Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
This is the fourth facility from the company to receive this registration
A Care network is a digital health network that connects healthcare stakeholders to deliver streamlined care with the patient at the centre of the experience
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Subscribe To Our Newsletter & Stay Updated
